Semaglutide & Tirzepatide: The Science Behind Modern Weight Loss
GLP-1 and GIP receptor agonist medications have transformed the field of weight management. Clinical trials have demonstrated average weight loss of 15–22% of body weight — results that were previously achievable only through bariatric surgery. At VPMC, Dr. Palagiri is a board-certified obesity medicine physician who prescribes and monitors these medications as part of a comprehensive, medically supervised weight loss program.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — a medication that mimics a natural hormone (glucagon-like peptide-1) your body produces after eating. This hormone signals your brain that you’re full, slows gastric emptying so you feel satisfied longer, and helps regulate blood sugar. Semaglutide is FDA-approved for weight management under the brand name Wegovy and for Type 2 diabetes under the brand name Ozempic.
Clinical trial results: The STEP trials demonstrated that patients on Semaglutide lost an average of 15% of their body weight over 68 weeks, with some patients losing significantly more. For a 250-pound patient, that translates to approximately 37 pounds.
What Is Tirzepatide?
Tirzepatide is a dual GLP-1/GIP receptor agonist — meaning it activates two appetite and metabolism pathways instead of one. This dual action may produce even greater weight loss for some patients. Tirzepatide is FDA-approved for weight management under the brand name Zepbound and for Type 2 diabetes under the brand name Mounjaro.
Clinical trial results: The SURMOUNT trials demonstrated that patients on Tirzepatide lost an average of 20–22% of their body weight, with the highest dose producing average weight loss of over 50 pounds in a 16-month period.
How These Medications Work
Both Semaglutide and Tirzepatide work by reducing appetite and cravings so you naturally eat less without constant hunger, slowing gastric emptying so you feel fuller longer after meals, improving insulin sensitivity and blood sugar regulation, and reducing visceral fat (the dangerous fat around your organs). These medications are administered as a once-weekly self-injection, typically in the abdomen or thigh. Doses are titrated gradually over several weeks to minimize side effects.
Who Is a Candidate?
At VPMC, Dr. Palagiri evaluates each patient individually. Generally, candidates include adults with a BMI of 30 or higher, adults with a BMI of 27 or higher with at least one weight-related condition (Type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, PCOS), patients who have not achieved adequate weight loss with diet and exercise alone, and patients seeking a medically supervised alternative to bariatric surgery.
Side Effects & Safety
The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — particularly during the dose titration period. These side effects are usually mild to moderate and improve over time. Serious side effects are rare but include pancreatitis risk and thyroid concerns (Semaglutide carries a boxed warning regarding medullary thyroid carcinoma based on animal studies).
At VPMC, we manage side effects proactively by starting at the lowest dose and titrating slowly, providing dietary guidance to minimize GI symptoms, monitoring labs regularly, and adjusting treatment if side effects persist.
Our Process
Your Semaglutide or Tirzepatide journey at VPMC follows a structured, physician-supervised protocol: initial comprehensive evaluation with Dr. Palagiri (medical history, lab work, body composition), prescription and first-dose guidance with titration schedule, regular follow-up visits (monthly) to monitor weight, side effects, and labs, ongoing nutrition counseling with our registered dietitian, and body composition tracking with InBody to distinguish fat loss from muscle loss.
This is not a “get the prescription and go” service. VPMC provides true medical supervision throughout your entire weight loss journey.
